News
Promising nonvaccine approaches to controlling dengue
As dengue vaccine development stumbles, nonpesticide-based mosquito control strategies gain traction.
News
EADV: Venous leg ulcers herald increased cancer risk
Venous leg ulceration appears to be a red flag for occult malignancy.
News
EADV: Intralesional therapy for scleroderma dystrophic calcifications
Intralesional sodium thiosulfate is an effective alternative to surgery for disabling dystrophic calcifications in patients with systemic...
News
EADV: No cancer signal with ixekizumab
To date, ixekizumab doesn’t raise any malignancy concerns in studies in psoriasis patients.
News
EADV: Fractional CO2 laser called ‘unmatched’ for hypertrophic burn scars
Key clinical point: Fractional CO2 laser therapy for hypertrophic burn scars provides unequaled improvements in skin softness and elasticity, as...
News
EADV: Secukinumab shows sustained high efficacy in SCULPTURE through 3 years
Key clinical point: Three-year data from a phase III trial provide reassurance regarding the long-term safety and efficacy of secukinumab for...
News
EADV: Spotlight on alexithymia in psoriasis
Key clinical point: Alexithymia is strikingly common among psoriasis patients and is associated with multiple psychiatric comorbidities and...
News
EADV: Best treatments for great saphenous vein reflux
Long-term outcomes for treatment of great saphenous vein reflux were significantly better with conventional surgery or endovenous laser ablation...
News
EADV: Another promising topical for atopic dermatitis
Key clinical point: The pipeline for nonsteroidal topical therapies for pediatric and adult atopic dermatitis shows great promise. Major finding:...
News
EADV: Long-term apremilast results show what to expect for psoriasis
Patients on apremilast for moderate to severe plaque psoriasis can reasonably anticipate a 50%-plus likelihood of a PASI-75 response after 52...
News
EADV: Hidradenitis suppurativa carries high cardiovascular risk
Key clinical point: Be vigilant in screening for modifiable cardiovascular risk factors in patients with hidradenitis suppurativa. Major finding:...
News
EADV: Ixekizumab promising for psoriatic arthritis
Key clinical point: The IL-17A inhibitor ixekizumab appears to be dramatically effective in psoriatic arthritis as well as in psoriasis. Major...
News
Investigational Biologic Rocks Psoriasis World
Key clinical point: An investigational inhibitor of the p19 subunit of interleukin-23 is generating efficacy results never before seen in...
News
EADV: Investigational biologic rocks psoriasis world
An investigational inhibitor of the p19 subunit of interleukin-23 is generating efficacy results never before seen in psoriasis.
News
EADV: Comorbid spondyloarthropathy common in hidradenitis suppurativa
Axial spondyloarthropathy is extremely common in patients with hidradenitis suppurativa.